CT-Screening beim Lungenkarzinom – wie ist die Evidenz?

Stand der Dinge

Bis heute gibt es in Deutschland kein anerkanntes Verfahren zur Früherkennung des Lungenkarzinoms. Lungenkrebs ist bei Männern die zweithäufigste, bei Frauen die dritthäufigste Krebserkrankung. Die Früherkennung des Lungenkarzinoms erhöht die Überlebenschance, da in den frühen Stadien eine kurative Lokaltherapie möglich ist. Da im Frühstadium aber meist keine klinischen Symptome auftreten, wird die Erkrankung häufig erst in fortgeschrittenen Stadien diagnostiziert.

Publikationsverlauf

Artikel online veröffentlicht:
01. April 2020

• Literatur

• 1 Goldstraw P, Chansky K, Crowley J. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11: 39-51
• 2 Fontana RS, Sanderson DR, Woolner LB. et al. Lung cancer screening: the Mayo program. J Occup Med 1986; 28: 746-750
• 3 Schmidt C. Lung cancer screening poised to expand. J Natl Cancer Inst 2015; 107: pii:djv114 . doi:10.1093/jnci/djv114
• 4 Becker N, Motsch E, Gross ML. et al. Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization. J Thorac Oncol 2015; 10: 890-896
• 5 Field JK, Duffy SW, Baldwin DR. et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016; 71: 161-170
• 6 Horeweg N, Scholten ET, de Jong PA. et al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncol 2014; 15: 1342-1350
• 7 Infante M, Cavuto S, Lutman FR. et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 2015; 191: 1166-1175
• 8 Paci E, Puliti D, Lopes Pegna A. et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017; 72: 825-831
• 9 Pastorino U, Rossi M, Rosato V. et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012; 21: 308-315
• 10 Wille MM, Dirksen A, Ashraf H. et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 2016; 193: 542-551
• 11 Aberle DR, Adams AM. National Lung Screening Trial Research T. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
• 12 MacMahon H, Naidich DP, Goo JM. et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017; 284: 228-243
• 13 Bach PB, Mirkin JN, Oliver TK. et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307: 2418-2429
• 14 Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437
• 15 Mehta A, Cordero J, Dobersch S. et al. Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. EMBO Mol Med 2016; 8: 1380-1389